Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Disis

Showing results (81-90 of 189) with videos related to

Pageof 19
Sort By:
Plos One|March 2, 2016
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell ActivityGregory N Dietsch, Hailing Lu, Yi Yang, et al.
Cancer Research|January 21, 2006
Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chainJames A Thompson, Samudra K Dissanayake, Bruce R Ksander, et al.
Journal of Clinical Immunology|September 15, 2005
Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cellsJunbao Yang, Laurel Huston, Deanna Berger, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic miceKeith L Knutson, Yushe Dang, Hailing Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2012
Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cellsYushe Dang, Wolfgang M Wagner, Ekram Gad, et al.
Breast Cancer Research and Treatment|November 15, 2014
Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor modelsEkram Gad, Lauren Rastetter, Meredith Slota, et al.
Biomaterials|April 27, 2010
Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironmentForrest M Kievit, Stephen J Florczyk, Matthew C Leung, et al.
Breast Cancer Research and Treatment|October 8, 2005
Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals"Masoud H Manjili, Hilal Arnouk, Keith L Knutson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 18, 2013
Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesionsElizabeth K Broussard, Rachel Kim, Jesse C Wiley, et al.
Innate Immunity|December 11, 2013
Protein-bound polysaccharide-K induces IL-1β via TLR2 and NLRP3 inflammasome activationYi Yang, Carol Inatsuka, Ekram Gad, et al.
Pageof 19

Showing results (81-90 of 189) with videos related to

Sort By:
Pageof 19
Plos One|March 2, 2016
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell ActivityGregory N Dietsch, Hailing Lu, Yi Yang, et al.
Cancer Research|January 21, 2006
Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chainJames A Thompson, Samudra K Dissanayake, Bruce R Ksander, et al.
Journal of Clinical Immunology|September 15, 2005
Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cellsJunbao Yang, Laurel Huston, Deanna Berger, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic miceKeith L Knutson, Yushe Dang, Hailing Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2012
Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cellsYushe Dang, Wolfgang M Wagner, Ekram Gad, et al.
Breast Cancer Research and Treatment|November 15, 2014
Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor modelsEkram Gad, Lauren Rastetter, Meredith Slota, et al.
Biomaterials|April 27, 2010
Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironmentForrest M Kievit, Stephen J Florczyk, Matthew C Leung, et al.
Breast Cancer Research and Treatment|October 8, 2005
Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals"Masoud H Manjili, Hilal Arnouk, Keith L Knutson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 18, 2013
Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesionsElizabeth K Broussard, Rachel Kim, Jesse C Wiley, et al.
Innate Immunity|December 11, 2013
Protein-bound polysaccharide-K induces IL-1β via TLR2 and NLRP3 inflammasome activationYi Yang, Carol Inatsuka, Ekram Gad, et al.
Pageof 19